RefleXion Medical is a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer.
RefleXion's technology aims to deliver high doses of radiation to tumors, even while in motion, for greater impact to the tumor with less dose to the surrounding tissue.
Reflexion medical was founded in 2009 by Sam Mazin and Akshay Nanduri. The company is headquartered in Hayward, California.
RefleXion is developing a biology-guided radiotherapy system, the RefleXion X1 machine, which is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).
RefleXion is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.
The BgRT recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for use in lung tumors because of its potential to detect and then immediately treat moving targets.
RefleXion is backed by TPG’s The Rise Fund, Sofinnova Partners, Ally Bridge Group, PSP Investments, KCK Group, T. Rowe Price, Venrock, Pfizer Ventures, JJDC, Ascension Ventures, and others. The company raised $80M in Series E round on Mar 10, 2022. This brings RefleXion's total funding to $445.1M to date.